{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:46Z","timestamp":1792708906695,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:33:04Z","timestamp":1792621984000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-114X","authenticated-orcid":false,"given":"A.","family":"El Helali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-1932","authenticated-orcid":false,"given":"C.","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-0549","authenticated-orcid":false,"given":"J.R.","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9351","authenticated-orcid":false,"given":"M.V.","family":"Cruz-Ordinario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-0494","authenticated-orcid":false,"given":"E.","family":"Kocakavuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7189-5883","authenticated-orcid":false,"given":"M. K-l.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-5428","authenticated-orcid":false,"given":"D.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1734-5772","authenticated-orcid":false,"given":"C.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-2900","authenticated-orcid":false,"given":"M.F.","family":"Mosele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-318X","authenticated-orcid":false,"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-2806","authenticated-orcid":false,"given":"D.","family":"Tamborero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-1891","authenticated-orcid":false,"given":"H.E.G.","family":"Russnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-0881","authenticated-orcid":false,"given":"M.","family":"Kordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-1106","authenticated-orcid":false,"given":"H.H.F.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-025X","authenticated-orcid":false,"given":"J.","family":"Rueter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"D.","family":"Martins-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C.B.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.annonc.2026.09.008_bib1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.008_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.008_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.008_bib4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41591-026-04280-2","article-title":"Real-world clinical utility of tumor whole-genome sequencing in solid cancers","volume":"32","author":"van Putten","year":"2026","journal-title":"Nat Med"},{"issue":"8099","key":"10.1016\/j.annonc.2026.09.008_bib5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41586-025-09812-3","article-title":"Whole-genome landscapes of 1,364 breast cancers","volume":"649","author":"Kim","year":"2026","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2026.09.008_bib7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib9","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.008_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.008_bib13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"issue":"7404","key":"10.1016\/j.annonc.2026.09.008_bib14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"7387","key":"10.1016\/j.annonc.2026.09.008_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"6349","key":"10.1016\/j.annonc.2026.09.008_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.008_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.008_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105110","article-title":"Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer","volume":"10","author":"Hong","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2026.09.008_bib20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.008_bib21","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.008_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamaoncol.2026.0127","article-title":"Genomic therapy matching in rare and refractory cancers","volume":"12","author":"Lin","year":"2026","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106027","article-title":"Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer","volume":"11","author":"Le","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC\u2013mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.008_bib26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.annonc.2026.09.008_bib28","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.annonc.2026.09.008_bib29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41591-025-04060-4","article-title":"AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer","volume":"32","author":"Li","year":"2026","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.008_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.trecan.2024.12.001","article-title":"Artificial intelligence-based biomarkers for treatment decisions in oncology","volume":"11","author":"Ligero","year":"2025","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.008_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","article-title":"HER2 testing: evolution and update for a companion diagnostic assay","volume":"22","author":"Robbins","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2026.09.008_bib36","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.annonc.2026.09.008_bib37","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO-25-02023","article-title":"Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non\u2013small cell lung cancer","volume":"43","author":"Johnson","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.008_bib43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"9742","key":"10.1016\/j.annonc.2026.09.008_bib46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.008_bib47","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.008_bib48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","article-title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","volume":"43","author":"Mayr","year":"2025","journal-title":"Cancer Cell"},{"issue":"10378","key":"10.1016\/j.annonc.2026.09.008_bib49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.008_bib50","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2025-266618","article-title":"Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation","volume":"18","author":"Mani","year":"2025","journal-title":"BMJ Case Rep"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.008_bib52","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib54","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/2159-8290.CD-15-0654","article-title":"EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib","volume":"5","author":"Gallant","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.008_bib55","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.annonc.2026.09.008_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cancergen.2022.03.001","article-title":"Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions","volume":"264-265","author":"Saliba","year":"2022","journal-title":"Cancer Genet"},{"issue":"16","key":"10.1016\/j.annonc.2026.09.008_bib57","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"10411","key":"10.1016\/j.annonc.2026.09.008_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.09.008_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djag220","article-title":"Impact of trop-2 expression on the efficacy of trop-2\u2013targeted antibody\u2013drug conjugates in metastatic breast cancer: a systematic review and meta-analysis","author":"Buonaiuto","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.008_bib60","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2026.09.008_bib61","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"216","key":"10.1016\/j.annonc.2026.09.008_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.008_bib63","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.008_bib65","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.008_bib66","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.008_bib67","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib69","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"10526","key":"10.1016\/j.annonc.2026.09.008_bib70","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.008_bib71","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.008_bib72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.008_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib74","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.008_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/cancers12030540","article-title":"MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma","volume":"12","author":"Forschner","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"29","key":"10.1016\/j.annonc.2026.09.008_bib76","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.008_bib78","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"issue":"7326","key":"10.1016\/j.annonc.2026.09.008_bib79","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"7377","key":"10.1016\/j.annonc.2026.09.008_bib80","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.008_bib81","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2026.09.008_bib82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41698-018-0073-y","article-title":"Utility of the JAX Clinical KnowledgeBase in capture and assessment of complex genomic cancer data","volume":"3","author":"Patterson","year":"2019","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib83","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s43018-022-00332-x","article-title":"The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.008_bib84","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng.3774","article-title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","volume":"49","author":"Griffith","year":"2017","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.008_bib85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:37:16Z","timestamp":1792708636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"alternative-id":["S0923753426066512"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}